BioXcel Therapeutics, Inc. (BTAI) Friday said the European Patent Office (EPO) has granted patent covering a range of sublingual dosage forms of dexmedetomidine including films, wafers, and tablets to treat agitation in people with dementia.
"The patent aligns with our focus on expanding our patent portfolio for BXCL501 into Europe, and, together with the United States and Japan, extends our BXCL501 franchise patent protection to three major markets. We believe this represents a strong foundation to potentially expand our commercialization of BXCL501 into additional geographies, if approved," said Vimal Mehta, CEO of BioXcel Therapeutics.
The United States Patent and Trademark Office (USPTO) had recently allowed patent application to method of treating agitation in patients with Alzheimer's disease using the oromucosal administration of dexmedetomidine.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.